Nearly 14 million people around the world learn that they have cancer every year. Another 8 million people die from the disease (according to the National Cancer Institute). To help in the mission to find a cure, the WIRB-Copernicus Group® (WCG™) has created WCG Oncology™, a comprehensive solution to enable the highest quality review of cancer research and to ensure the rights and welfare of research participants.
THE THREE FACETS OF WCG ONCOLOGY INCLUDE:
GEORGE DEMETRI, MD
Dana-Farber Cancer Institute
JOHN M. FALLETTA, MD
Duke University Medical Center
ARNOLD J. LEVINE, PHD
Institute for Advanced Study, School of Natural Sciences
JOHN E. NIEDERHUBER, MD
Inova Translational Medicine Institute;
Former Head of the National Cancer Institute
JAMES ROTHMAN, PHD
Yale University; Recipient, Nobel Prize in Medicine, 2013
HOWARD SCHER, MD
Memorial Sloan Kettering Cancer Center
Human gene therapy is one of the fastest-growing areas of medical research, and one of the most promising. The advances made by scientists and clinicians in the field of gene therapy have enabled us to target disease at the genetic level.
As gene therapy research moves increasingly into the clinic, we must ensure that our clients are well prepared to safely and confidently manage this new type of research. Through WCG Gene Therapy™, our clients have access to the best and most current thinking in this new and emerging field.
WCG Gene Therapy combines our unmatched review and consulting capabilities with the insights of experts from diverse backgrounds with specialized knowledge of the clinical development, regulatory oversight, and clinical application of products involving recombinant DNA, to help our clients safely manage increasing volumes of this complex and potentially hazardous research.
Through our relationship with WCG, we have evaluated over 250 human gene transfer protocols to date – more than any organization outside of the Food and Drug Administration (FDA) and the National Institute of Health (NIH).
MARK BAGARAZZI, MD
Chief Medical Officer, Inovio Pharmaceuticals
CARL JUNE, MD
Director of Translational Research, Penn Medicine
HANS-PETER KIEM, MD, Dr med.
Chair, Recombinant DNA Advisory Committee (RAC);
Head of Heme Malignancy Program, University of Washington/
Fred Hutchinson Cancer Research Center
ARNOLD J. LEVINE, PHD
Professor, Institute for Advanced Study, School of Natural Sciences
TONY REID, MD, PHD
Chair, Association of American Cancer Institutes;
Professor, University of California San Diego